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Technical Update on HIV-1/2 Differentiation Assays 
In response to changes in the commercial availability of HIV-1/HIV-2 antibody 
differentiation assays approved by the U.S. Food and Drug Administration (FDA) for diagnostic 
use, the Centers for Disease Control and Prevention (CDC) and the Association of Public 
Health Laboratories (APHL) are writing to share information on the only available differentiation 
assay as well as interim solutions for HIV testing.  
The CDC and APHL continue to recommend that laboratories use a laboratory-based HIV 
antigen/antibody HIV screening immunoassay, followed, when reactive, by an HIV-1/HIV-2 
antibody differentiation immunoassay. When the differentiation assay returns a negative or 
indeterminate result, perform an HIV-1 nucleic acid test (NAT).1 In addition to being accurate, 
HIV testing should be expedited to reduce the time to antiretroviral treatment because infected 
persons have better health outcomes when they are treated earlier and treatment of infected 
persons reduces transmission of HIV to others. 
Results provided by new HIV-1/HIV-2 antibody differentiation supplemental assay 
There is one FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay for 
supplemental testing that continues to be manufactured (Geenius™ HIV 1/2 Supplemental 
Assay, Redmond, WA). Its package insert provides test result reporting language that should 
be followed. The test produces three results not generated by its predecessor: HIV-2 positive 
with HIV-1 cross reactivity, HIV-2 indeterminate, and HIV indeterminate.2  
• An HIV-2 positive with HIV-1 cross reactivity result should be considered HIV-2 
positive. This result is distinct from HIV positive untypable (undifferentiated), which 
would indicate the possibility of dual infection with HIV-1 and HIV-2. Persons with 
either result should be referred to medical care.  
• Specimens with HIV-2 indeterminate results require additional testing. First, Geenius 
testing should be repeated with the same specimen. If the specimen tests HIV-
negative on repeat this should be reported as the final result for the Geenius and 
testing with an HIV-1 NAT is indicated. If the specimen is repeatedly HIV-2 
indeterminate, then according to the package insert,3 testing should be repeated 2-4  
 
 
• weeks later with a new specimen. However, data presented at the 2016 HIV 
Diagnostics Conference that became available after FDA approved the package 
insert indicate that some persons with repeatedly HIV-2 indeterminate results have 
acute HIV-1 infectiion.4-6 If a specimen repeatedly produces HIV-2 indeterminate 
results, an HIV-1 NAT should be conducted. If HIV-1 RNA is detected by NAT, this 
result indicates acute HIV-1 infection, and the person should be referred for 
immediate medical care. If the HIV-1 NAT result is negative, refer the specimen for 
testing with a different validated supplemental HIV-2 test (antibody test or NAT) or 
repeat testing in 2 to 4 weeks. Supplemental HIV-2 testing may be available through 
commercial laboratories, public health laboratories or CDC.  
• HIV indeterminate results should prompt the same testing sequence as described 
above for repeatedly HIV-2 indeterminate results. First, an HIV-1 NAT should be 
conducted. If HIV-1 RNA is detected by NAT, this result indicates acute HIV-1 
infection, and the person should be referred for immediate medical care. If the HIV-1 
NAT result is negative, refer the specimen for testing with a different validated 
supplemental HIV-2 test (antibody test or NAT) or repeat testing in 2 to 4 weeks. 
Supplemental HIV-2 testing may be available through commercial laboratories, 
public health laboratories or CDC. 
There may be circumstances under which a laboratory is unable to adopt the FDA-
approved HIV-1/HIV-2 antibody differentiation immunoassay. In this situation, a laboratory has 
alternatives for that step in the algorithm, some of which could delay turnaround time for test 
results.  
• Send specimens to another laboratory that offers the FDA-approved supplemental HIV 
antibody differentiation assay.  
• Refer to CDC/APHL laboratory testing guidance section I, “Alternative Testing 





• Validate another HIV test for use as a supplemental antibody test. A validated test is 
one for which an individual laboratory has demonstrated the ability to produce accurate 
results according to the standards of the Clinical Laboratory Improvement Amendments 
(CLIA) or other regulatory entities and can therefore be used to report clinical results for 
diagnosis and patient management.  
 
There will remain cases for which diagnostic tests and algorithms are not accurate. 
Biologic causes for false-positive and false-negative HIV test results have been reported. Pre- 
and post-analytic steps such as incorrect specimen type, specimen mix-up, mislabeling or data 
transcription errors can also lead to incorrect HIV test results. Inconsistent or conflicting test 
results should therefore be investigated with follow-up testing on a newly collected specimen. 
Thank you for your commitment to accurate laboratory testing for HIV. Please send any 
comments or questions to www.cdc.gov/info or 1-800-CDC-INFO. 
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